Shanghai, China

Qianqian Shan

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Harbour Biomed (Shanghai) Co., Ltd. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qianqian Shan. Retrieved from https://idiyas.com/inventor/qianqian-shan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Qianqian Shan: Innovator in Antigen-Binding Proteins

Introduction

Qianqian Shan is a notable inventor based in Shanghai, China. She has made significant contributions to the field of biotechnology, particularly in the development of antigen-binding proteins. Her work is crucial in advancing therapeutic options for various diseases.

Latest Patents

Qianqian Shan holds a patent for a PD-1 antigen-binding protein and its use. This innovation is pivotal in the ongoing research and development of immunotherapies, which aim to enhance the body's immune response against cancer.

Career Highlights

Currently, Qianqian Shan is employed at Harbour Biomed (Shanghai) Co., Ltd. Her role at the company allows her to engage in cutting-edge research and collaborate with other experts in the field.

Collaborations

Some of her notable coworkers include Haishan Luo and Xuekun Zhang. Their collective expertise contributes to the innovative environment at Harbour Biomed.

Conclusion

Qianqian Shan's work in antigen-binding proteins exemplifies the impact of innovation in biotechnology. Her contributions are paving the way for new therapeutic strategies that could benefit many patients in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…